ERBB2 and osteosarcoma: Currently, potential effective targets for CAR-T cell therapy in osteosarcoma include HER2, IGF1R, ROR1, EphA2, CSPG4, folate receptor with EC17, B7-H3, GD2, NKG2D, ALCAM/CD166, IL-11Rα, and FAP.